跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

V0100000

维拉帕米

European Pharmacopoeia (EP) Reference Standard

别名:

（±）-维拉帕米 盐酸盐, 5-[N-（3，4-二甲氧基苯基乙基）甲胺基]-2-（3，4-二甲氧基苯基）-2-异丙基戊腈α； 盐酸盐

登录查看公司和协议定价
所有图片(1)

About This Item

线性分子式:
(CH3O)2C6H3CH2CH2N(CH3)(CH2)3C[C6H3(OCH3)2][CH(CH3)2]CN · HCl
CAS号:
152-11-4
分子量:
491.06
Beilstein:
3647093
MDL编号:
MFCD00055208
UNSPSC代码:
41116107
PubChem化学物质编号:
329828921
NACRES:
NA.24

等级

pharmaceutical primary standard

Agency

EP Reference Standard

API类

verapamil

制造商/商品名称

EDQM

mp

142 °C (dec.) (lit.)

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

Cl.COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC

InChI

1S/C27H38N2O4.ClH/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6;/h9-12,17-18,20H,8,13-16H2,1-7H3;1H

InChI key

DOQPXTMNIUCOSY-UHFFFAOYSA-N

基因信息

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Verapamil hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

α1-肾上腺素受体拮抗剂；L型钙通道阻滞剂。
α1-肾上腺素受体拮抗剂；L型钙通道阻滞剂。阻断平滑肌和心肌中的 L 型 Ca2+ 通道，体外诱导人原发性和转移性结肠癌细胞的凋亡。对 PGP 起作用的抗药性逆转剂，如减少肾小管清除地高辛。增加 Pgp 的基础 ATP 酶活性。Cyp3A4 和 CYP2C6 的底物。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesEnvironment
GHS06,GHS09

警示用语：

Danger

危险声明

H301,H411

危险分类

Acute Tox. 3 Oral - Aquatic Chronic 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Jian-Min Shen et al.
Pharmacological research, 70(1), 102-115 (2013-02-05)
In this paper we give a method of integrated treatment for cancer and drug-induced complications in the process of cancer therapy through dual-drug delivery system (DDDS). Two hydrophilic drugs, doxorubicin (an antitumor drug) and verapamil (an antiangiocardiopathy drug) combined preliminarily
Rania Soudy et al.
Journal of medicinal chemistry, 56(19), 7564-7573 (2013-09-14)
The efficacy of chemotherapeutic doxorubucin (Dox) in cancer treatment is limited by two main factors, nonspecific toxicity and the emergence of tumor resistance. To overcome these hurdles, in this study peptide-Dox conjugates were prepared. A decapeptide 18-4a (NH₂-WxEAAYQkFL-CONH₂) [corrected] with
Maria Feldmann et al.
The Lancet. Neurology, 12(8), 777-785 (2013-06-22)
Studies in rodent models of epilepsy suggest that multidrug efflux transporters at the blood-brain barrier, such as P-glycoprotein, might contribute to pharmacoresistance by reducing target-site concentrations of antiepileptic drugs. We assessed P-glycoprotein activity in vivo in patients with temporal lobe
Alice Ban Ke et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(3), 437-446 (2013-01-30)
Through PET imaging, our laboratory has studied the dynamic biodistribution of (11)C-verapamil, a P-gp substrate, in the nonhuman primate Macaca nemestrina. To gain detailed insight into the kinetics of verapamil transport across the blood-brain barrier (BBB) and the blood-placental barrier
Shashank Gupta et al.
American journal of respiratory and critical care medicine, 188(5), 600-607 (2013-06-29)
A major priority in tuberculosis (TB) is to reduce effective treatment times and emergence of resistance. Recent studies in macrophages and zebrafish show that inhibition of mycobacterial efflux pumps with verapamil reduces the bacterial drug tolerance and may enhance drug
查看所有相关文献

实验方案

LC/MS/MS Analysis of Interacting Cardiac Drugs Digoxin, Quinidine, Amiodarone and Verapamil on Titan™ C18

LC/MS/MS Analysis of Interacting Cardiac Drugs Digoxin, Quinidine, Amiodarone and Verapamil on Titan™ C18

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门